Measurement of plasma ammonia is affected in patients receiving asparaginase therapy [3]

Clinical Chemistry

Volumn 49, Issue 10, 2003, Pages 1710-1711

  Laterza, Omar F ^a   Gerhardt, Greg ^a   Sokoll, Lori J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 DIAZO 4 OXONORVALINE; AMMONIA; ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARTIC ACID BETA SEMIALDEHYDE; ENZYME INHIBITOR; GLUTAMINE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; AMMONIA BLOOD LEVEL; AMMONIA FORMATION; BIOASSAY; CANCER CHEMOTHERAPY; CASE REPORT; CHILD; ENZYME ACTIVITY; ENZYME THERAPY; HUMAN; LABORATORY DIAGNOSIS; LETTER; MEDICAL RECORD;

AMMONIA; ANTINEOPLASTIC AGENTS; ASPARAGINASE; HUMANS; KINETICS; TIME FACTORS;

EID: 0141504211     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.10.1710     Document Type: Letter

References (3)

1. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL [Review]. Crit Rev Oncol Hematol 1998;28:97-113.
2. Leonard JV, Kay JDS. Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet 1986;1:162-3.
3. Asselin BL, Lorenson MY, Whitin JC, Coppola DJ, Kende AS, Blakley RL, et al. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res 1991;51:6568-73.